These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37280655)

  • 1. More efficient and inclusive time-to-event trials with covariate adjustment: a simulation study.
    Momal R; Li H; Trichelair P; Blum MGB; Balazard F
    Trials; 2023 Jun; 24(1):380. PubMed ID: 37280655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Covariate adjustment in randomized controlled trials with dichotomous outcomes increases statistical power and reduces sample size requirements.
    Hernández AV; Steyerberg EW; Habbema JD
    J Clin Epidemiol; 2004 May; 57(5):454-60. PubMed ID: 15196615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mind the gap: covariate constrained randomisation can protect against substantial power loss in parallel cluster randomised trials.
    Kristunas C; Grayling M; Gray LJ; Hemming K
    BMC Med Res Methodol; 2022 Apr; 22(1):111. PubMed ID: 35413793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of inverse probability weighting using the propensity score for baseline covariate adjustment in smaller population randomised controlled trials with a continuous outcome.
    Raad H; Cornelius V; Chan S; Williamson E; Cro S
    BMC Med Res Methodol; 2020 Mar; 20(1):70. PubMed ID: 32293286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized controlled trials with time-to-event outcomes: how much does prespecified covariate adjustment increase power?
    Hernández AV; Eijkemans MJ; Steyerberg EW
    Ann Epidemiol; 2006 Jan; 16(1):41-8. PubMed ID: 16275011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of covariate adjustment approaches under model misspecification in individually randomized trials.
    Tackney MS; Morris T; White I; Leyrat C; Diaz-Ordaz K; Williamson E
    Trials; 2023 Jan; 24(1):14. PubMed ID: 36609282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Covariate adjustment in Bayesian adaptive randomized controlled trials.
    Willard J; Golchi S; Moodie EE
    Stat Methods Med Res; 2024 Mar; 33(3):480-497. PubMed ID: 38327082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increasing the efficiency of randomized trial estimates via linear adjustment for a prognostic score.
    Schuler A; Walsh D; Hall D; Walsh J; Fisher C; ; ;
    Int J Biostat; 2022 Nov; 18(2):329-356. PubMed ID: 34957728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studies.
    Kahan BC; Jairath V; Doré CJ; Morris TP
    Trials; 2014 Apr; 15():139. PubMed ID: 24755011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Covariate adjustment had similar benefits in small and large randomized controlled trials.
    Thompson DD; Lingsma HF; Whiteley WN; Murray GD; Steyerberg EW
    J Clin Epidemiol; 2015 Sep; 68(9):1068-75. PubMed ID: 25497979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline characteristics and statistical power in randomized controlled trials: selection, prognostic targeting, or covariate adjustment?
    Roozenbeek B; Maas AI; Lingsma HF; Butcher I; Lu J; Marmarou A; McHugh GS; Weir J; Murray GD; Steyerberg EW;
    Crit Care Med; 2009 Oct; 37(10):2683-90. PubMed ID: 19885979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Covariate adjustment in subgroup analyses of randomized clinical trials: A propensity score approach.
    Yang S; Li F; Thomas LE; Li F
    Clin Trials; 2021 Oct; 18(5):570-581. PubMed ID: 34269087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Covariate Adjustment in Cardiovascular Randomized Controlled Trials: Its Value, Current Practice, and Need for Improvement.
    Pirondini L; Gregson J; Owen R; Collier T; Pocock S
    JACC Heart Fail; 2022 May; 10(5):297-305. PubMed ID: 35483791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Residual Risk-Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies.
    Wei W; Kurita T; Hess KR; Sanft T; Szekely B; Hatzis C; Pusztai L
    JAMA Oncol; 2018 Apr; 4(4):e175092. PubMed ID: 29372234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonparametric covariate adjustment in estimating hazard ratios.
    Jiang H; Kulkarni PM; Wang Y; Mallinckrodt CH
    Pharm Stat; 2016; 15(1):46-53. PubMed ID: 26610282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empirical likelihood inference in randomized clinical trials.
    Zhang B
    Stat Methods Med Res; 2018 Dec; 27(12):3770-3784. PubMed ID: 28679341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment and implication of prognostic imbalance in randomized controlled trials with a binary outcome--a simulation study.
    Chu R; Walter SD; Guyatt G; Devereaux PJ; Walsh M; Thorlund K; Thabane L
    PLoS One; 2012; 7(5):e36677. PubMed ID: 22629322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "Super-covariates": Using predicted control group outcome as a covariate in randomized clinical trials.
    Holzhauer B; Adewuyi ET
    Pharm Stat; 2023; 22(6):1062-1075. PubMed ID: 37553959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the relevance of prognostic information for clinical trials: A theoretical quantification.
    Siegfried S; Senn S; Hothorn T
    Biom J; 2023 Jan; 65(1):e2100349. PubMed ID: 35934915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.